There is an obvious trend that pancreatic fistula can not only delay but prohibit adjuvant therapy because chronic abdominal infection due to the fistula affects the performance status and the convalescence of the patient.
← all excerpts
Adjuvant gemcitabine after resection of pancreatic cancer without significant difference in overall survival: a retrospective cohort study.
1
—
—